Document:

Exhibit
10.5 

 

Vitro
Biopharma, Inc.

2022
Omnibus Incentive Compensation Plan

Notice
of Stock Option Grant

 

You
have been granted the following option to purchase shares of the common stock of Vitro Biopharma, Inc. (the “Company”):

 

	 	Name
    of Participant:	 
	 	 	 
	 	Total
    Number of Shares:	 
	 	 	 
	 	Type
    of Option:	Nonstatutory
    Stock Option (NSO)
	 	 	 
	 	Exercise
    Price per Share:	$
	 	 	 
	 	Date
    of Grant:	 
	 	 	 
	 	Vesting
    Commencement Date:	 
	 	 	 
	 	Vesting
    Schedule:	This
option vests and becomes exercisable with respect to twenty-five percent of the shares of common stock of the Company (“Shares”)
subject to this option on the first anniversary of the Date of Grant, with each additional twenty-five percent of the Shares subject
to this option vesting on the next successive anniversaries of the Date of Grant, such that one hundred percent of the Shares subject
to this option become vested on the fourth anniversary of the Date of Grant subject to your Continuous Service (as defined below in the
Stock Option Agreement) not being terminated on each such vesting date.
	 	 	 
	 	 	If
the Company is subject to a “Change in Control” (As defined in in the Company’s 2022 Omnibus Incentive Compensation
Plan (the “Plan”)) and your Continuous Service has not terminated as the closing date of the Change in Control, then
the vesting of any then-unvested portion of your option shall accelerate in full such that 100% of the then unvested Shares underlying
such option will become vested and exercisable as of the closing date of the Change in Control.
	 	 	 
	 	Expiration
    Date:	[Month]
    [XX], 20[XX]. This option expires earlier if your Continuous Service terminates earlier, as described in the Stock Option Agreement,
    and may terminate earlier in connection with certain corporate transactions as described in Article 14 of the Plan.

 

You
and the Company agree that this option is granted under and governed by the terms and conditions of the Plan and the Stock Option Agreement,
both of which are attached to, and made a part of, this document. All capitalized terms used in this Notice of Stock Option Grant shall
have the meanings assigned to them in the Stock Option Agreement, the Notice of Stock Option Grant or the Plan.

 

You
further agree to accept by email all documents relating to the Plan or this option and all other documents that the Company is required
to deliver to its security holders. You also agree that the Company may deliver these documents by posting them on a website maintained
by the Company or by a third party under contract with the Company. If the Company posts these documents on a website, it will notify
you by email.

 

	Participant	 	Vitro Biopharma, Inc.
	 	 	 	 
	 	 	By:	           
	 	 	Title:
    	 

 

    	 

     

    

 

Vitro
Biopharma, Inc.

2022
Omnibus Incentive Compensation Plan

Stock
Option Agreement

 

	Grant
    of Option	 	Subject
                                            to all of the terms and conditions set forth in the Notice of Stock Option Grant, this Stock
                                            Option Agreement (the “Agreement”) and the Plan, the Company has granted
                                            you an option to purchase up to the total number of shares of common stock of the Company
                                            (“Shares”) specified in the Notice of Stock Option Grant at the exercise
                                            price indicated in the Notice of Stock Option Grant.

     

    All
    capitalized terms used in this Agreement shall have the meanings assigned to them in this Agreement, the Notice of Stock Option Grant
    or the Plan.

	 	 	 
	Tax
    Treatment	 	This
    option is a nonstatutory stock option, as provided in the Notice of Stock Option Grant. 
	 	 	 
	Vesting	 	This
                                            option vests and becomes exercisable in accordance with the vesting schedule set forth in
                                            the Notice of Stock Option Grant.

     

    In
    no event will this option vest or become exercisable for additional Shares after your Continuous Service has terminated for any reason.

	 	 	 
	Term	 	This
    option expires in any event at the close of business at Company headquarters on the day before the 10th anniversary of
    the Date of Grant, as shown in the Notice of Stock Option Grant. (This option will expire earlier if your Continuous Service terminates,
    as described below, and this option may be terminated earlier as provided in Article 14 of the Plan.)
	 	 	 
	Termination
    of Continuous Service	 	If
                                            your Continuous Service terminates for any reason, this option will expire immediately to
                                            the extent the option is unvested as of your termination date and does not vest as a result
                                            of your termination of Continuous Service. The Committee determines when your Continuous
                                            Service terminates for all purposes of this option in accordance with the below definition
                                            of Continuous Service.

     

    For
    purposes of this Agreement, Continuous Service means that your service with the Company, a Subsidiary or an Affiliate, whether as
    an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which you renders service to the
    Company, Subsidiary or an Affiliate as an Employee, Consultant or Director or a change in the entity for which you render such service,
    provided that there is no interruption or termination of your service with the Company, a Subsidiary or an Affiliate, will not terminate
    your Continuous Service. 

 

    	2

     

    

 

	Regular
    Termination	 	If
                                            your Continuous Service terminates for any reason except death, total and permanent Disability
                                            or Cause (as defined below), then this option, to the extent vested as of your termination
                                            date, will expire at the close of business at Company headquarters on the date three months
                                            after your termination date.

     

    Notwithstanding
    anything in this Agreement to the contrary, in no event will your option be exercisable after the Expiration Date.

	 	 	 
	Death	 	If
    your Continuous Service terminates as a result of your death, then this option will expire at the earlier of (i) the close of business
    at Company headquarters on the date 12 months after the date of death or (ii) the Expiration Date.
	 	 	 
	Disability	 	If
    your Continuous Service terminates because of your Disability, then this option will expire at the earlier of (i) the close of business
    at Company headquarters on the date 12 months after your termination date or (ii) the Expiration Date.
	 	 	 
	Termination
    of Continuous Service for Cause	 	Notwithstanding
                                            anything in this Agreement to the contrary, in the event your Continuous Service is terminated
                                            for Cause, you will immediately and automatically forfeit all options granted to you including
                                            all vested and unvested rights to purchase Shares thereunder.

     

    If
    your Continuous Service is terminated as a result of any of the following, as determined by the Committee, you will be considered
    to have been terminated for Cause:

 

	 	●	commission
    of an act of fraud, embezzlement or other act of dishonesty that would reflect adversely on the Company’s, its Subsidiaries’
    or Affiliates’ integrity, character or reputation, or that would cause harm to the Company’s or its Subsidiaries’
    or its Affiliates’ operations or business prospects;
	 	 	 
	 	●	breach
    of a fiduciary duty owed to the Company, its Subsidiaries or its Affiliates;
	 	 	 
	 	●	violation
    or threatening to violate a restrictive covenant agreement, such as a non-compete, non-solicit, or non-disclosure agreement, between
    you and the Company, a Subsidiary or an Affiliate;
	 	 	 
	 	●	unauthorized
    disclosure or use of confidential information or trade secrets of the Company, a Subsidiary or Affiliate;
	 	 	 
	 	●	violation
    of any of the Company’s, its Subsidiaries’ or its Affiliates’ lawful policies or rules, including any applicable
    code of conduct;
	 	 	 
	 	●	commission
    of criminal activity;
	 	 	 
	 	●	failure
    to reasonably cooperate in any investigation or proceeding concerning the Company, a Subsidiary or an Affiliate; or
	 	 	 
	 	●	neglect
    or misconduct in the performance of your duties and responsibilities, provided that, if curable, you did not cure such neglect or
    misconduct within ten (10) days after you were provided written notice of such neglect or misconduct.

 

	 	 	Notwithstanding
    the above, if you have an employment agreement with the Company, a Subsidiary or an Affiliate that contains a different definition
    of cause, then the definition contained in your employment agreement will control. The determination as to whether you are terminated
    for Cause will be made in the sole discretion of the Company.

 

    	3

     

    

 

	Leaves
    of Absence and Part-Time Work	 	For
                                            purposes of this option, your Continuous Service does not terminate when you go on a military
                                            leave, a sick leave or another bona fide leave of absence, if the leave was approved
                                            by the Company in writing and if continued crediting of service is required by applicable
                                            law, the Company’s leave of absence policy, or the terms of your leave.

     

    If
    you go on a leave of absence, then the vesting schedule specified in the Notice of Stock Option Grant may be adjusted in accordance
    with the Company’s leave of absence policy or the terms of your leave. If you commence working on a part-time basis, the Company
    may adjust the vesting schedule so that the rate of vesting is commensurate with your reduced work schedule.

	 	 	 
	Restrictions
    on Exercise	 	The
    Company will not permit you to exercise this option if the issuance of Shares at that time would violate any law or regulation.
	 	 	 
	Notice
                                            of Exercise

     

     
	 	When
                                            you wish to exercise this option, you must submit to the Company a written notice of exercise
                                            that identifies this Agreement and states the number of Shares being purchased, in accordance
                                            with any instructions or forms provided by the Company. The notice will be effective when
                                            the Company receives it. As determined by the Company, in order to effectively exercise your
                                            option, you may also be required to execute and provide certain agreements, statements or
                                            other evidence that the Company may require, including a joinder agreement to the stockholder
                                            agreement of the Company and any documents required by the Company to satisfy itself that
                                            the issuance of the Shares upon exercise (and any subsequent resale of the Shares) will be
                                            in compliance with applicable laws and regulations and any shareholder agreement of the Company.

     

    In
    the event of your death, your designated beneficiary may exercise this option to the extent you would have been entitled to as of
    the date of your death. In order to exercise your option, your beneficiary must be properly designated in writing with the Company
    and not revoked. In the event you do not have a proper beneficiary designation on file with the Company, the option may be exercised
    by your estate.

     

    You
    may only exercise your option for whole Shares.

 

    	4

     

    

 

	Form
    of Payment	 	When
you submit your notice of exercise, you must include payment of the option exercise price for the Shares that you are purchasing. To
the extent permitted by applicable law, payment may be made in one (or a combination of two or more) of the following forms:

 

	 	●	By
    delivering to the Company your personal check, a cashier’s check or a money order, or arranging for a wire transfer.
	 	 	 
	 	●	By
    delivery to the Company (either by actual delivery or attestation) of previously owned Shares that are owned free and clear of any
    liens, claims, encumbrances or security interests. The Fair Market Value of the Shares will be determined as of the effective date
    of the option exercise. The Option may not be exercised by delivery to the Company of previously owned Shares if doing so would violate
    the provisions of any law, regulation or agreement restricting the redemption of the Shares.
	 	 	 
	 	●	By
    a “net exercise” arrangement pursuant to which the Company will reduce the number of Shares issued upon exercise of the
    option by the largest whole number of Shares with a Fair Market Value that does not exceed the aggregate exercise price. You must
    pay any remaining balance of the aggregate exercise price not satisfied by the “net exercise” in cash or other permitted
    form of payment.
	 	 	 
	 	●	By
    a combination of the three above methods.

 

	Withholding
    Taxes	 	You
will not be allowed to exercise this option unless you make arrangements acceptable to the Company to pay any withholding taxes that
may be due as a result of the option exercise. These arrangements include (a) payment in cash, (b) withholding Shares that otherwise
would be issued to you when you exercise this option with a Fair Market Value no greater than the minimum amount required to be withheld
by law, (c) surrendering Shares that you previously acquired with a Fair Market Value no greater than the minimum amount required to
be withheld by law, or (d) withholding cash from other compensation. The Fair Market Value of withheld or surrendered Shares, determined
as of the date when taxes otherwise would have been withheld in cash, will be applied to the withholding taxes.
	 	 	 
	Transfer
                                            of Option

     

     
	 	Prior
    to your death, only you may exercise this option. You cannot transfer or assign this option. For instance, you may not sell this
    option or use it as security for a loan. If you attempt to do any of these things, this option will immediately become invalid. You
    may, however, dispose of this option in your will or by means of a written beneficiary designation; provided, however, that your
    beneficiary or a representative of your estate acknowledges and agrees in writing in a form reasonably acceptable to the Company,
    to be bound by the provisions of this Agreement and the Plan as if such beneficiary of the estate were you.

 

    	5

     

    

 

	Market
                                                                     Stand-Off Agreement

     

     
	 	If
    requested by the Company or the managing underwriter pursuant to any proposed public offering of the Company’s securities,
    you agree that you will not, directly or indirectly, sell, lend, pledge, offer, transfer, make any short sale of, sell any option
    or contract to purchase, contract to sell, purchase any option or contract to sell, grant any option, right or warrant for the purchase
    of, otherwise transfer or dispose of, or enter into any hedging or similar transaction with the same economic effect as a sale, any
    Shares held by Optionee immediately prior to the effectiveness of the registration statement for such public offering for a period
    specified by the Company or the managing underwriter for such offering, which period shall not exceed one hundred eighty (180) days
    following the effective date of the public offering. You further agree to execute such agreements as may be reasonably requested
    by the Company or the managing underwriter for such offering that are consistent with this provision of the Agreement or that are
    necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop transfer instructions
    with respect to the Shares until the end of such period. 
	 	 	 
	Employment
    Rights	 	Your
    option or this Agreement does not give you the right to be employed by the Company, Subsidiary, or an Affiliate in any capacity.
    The Company, its Subsidiaries and Affiliates reserve the right to terminate your Continuous Service at any time, with or without
    Cause.
	 	 	 
	Stockholder
    Rights	 	You,
    or your estate or heirs, have no rights as a stockholder of the Company until you have exercised this option by giving the required
    notice to the Company, paying the exercise price, satisfying any applicable withholding taxes, the transfer of the Shares to you
    by the Company or the transfer agent and your name being been entered as the stockholder of record on the books of the Company. No
    adjustments are made for dividends or other rights if the applicable record date occurs before you exercise this option, except as
    described in the Plan.
	 	 	 
	Recoupment
    Policy	 	This
    option, and the Shares acquired upon exercise of this option, shall be subject to any Company recoupment policy in effect from time
    to time.
	 	 	 
	Adjustments	 	In
    the event of a stock split, a stock dividend or a similar change in Company stock, the number of Shares covered by this option and
    the exercise price per Share will be adjusted pursuant to the Plan.
	 	 	 
	Effect
    of Significant Corporate Transactions	 	If
    the Company is a party to a merger, consolidation, or certain change in control transactions, then this option will be subject to
    the applicable provisions of Articles 4 and 14 of the Plan.
	 	 	 
	Applicable
    Law	 	This
    Agreement will be interpreted and enforced under the laws of the State of Nevada (without regard to its choice-of-law provisions).
	 	 	 
	The
    Plan and Other Agreements	 	The
                                            text of the Plan is incorporated in this Agreement by reference.

     

    This
    Plan, this Agreement and the Notice of Stock Option Grant constitute the entire understanding between you and the Company regarding
    this option. Any prior agreements, commitments or negotiations concerning this option are superseded. This Agreement may be amended
    only by another written agreement between the parties.

 

By
signing the cover sheet of this Agreement, you agree to all of the terms and conditions described above and in the Plan.

 

    	6Exhibit
10.7 

 

VITRO
DIAGNOSTICS, INC.

 

NON-STATUTORY
STOCK OPTION AGREEMENT

 

This
Non-Statutory Stock Option Agreement (the “Agreement”) is made and entered into effective the 1st day of May, 2018, between
Vitro Diagnostics, Inc., (the “Company”) and James Musick(“Optionee”).

 

NOW,
THEREFORE, it is hereby agreed as follows:

 

1.
Grant of Option. The Company hereby grants to Optionee, as of the date hereof, an option to purchase commencing on the date hereof
and ending on the tenth (10th) anniversary of the date hereof (the “Expiration Date”) an option exercisable to
purchase up to an aggregate of 4.3 million shares of Common Stock, $.001 par value, (the “Option Shares”) at an exercise
price of $0.05 per Option Share (the “Exercise Price”). The Option Shares shall be purchasable from time to time during the
option term specified in this Section 1 at the Exercise Price, subject to the vesting provisions of paragraph 3 of this Option.

 

2.
Option Term. This option shall expire at the close of business on the Expiration Date or on the date on which the option shall
have been exercised in full (the “Exercise Date”), unless sooner terminated in accordance with Section 5 hereof.

 

3.
Vesting. This Option is subject to the vesting schedule set forth in this paragraph 3. Only Options that have vested will be
exercisable by Optionee. To vest, Optionee must continue to be in Service with the Company on each Vesting Date. The number of
Options to vest on each Vesting Date is as follows:

 

	Number
    of Options	 	Vesting
    Date
	 	 	 
	860,000	 	Upon
    issuance
	 	 	 
	860,000	 	One
    year anniversary of grant date
	 	 	 
	860,000	 	Two
    year anniversary of grant date
	 	 	 
	860,000	 	Three
    year anniversary of grant date
	 	 	 
	860,000	 	Four
    year anniversary of grant date

 

4.
Limited Transferability.

 

(a)
This option shall be neither transferable nor assignable by Optionee other than by will or the laws of inheritance following Optionee’s
death and may be exercised, during Optionee’s lifetime, only by Optionee. However, Optionee may designate one or more persons as
the beneficiary or beneficiaries of this option, and this option shall, in accordance with such designation, automatically be transferred
to such beneficiary or beneficiaries upon the Optionee’s death while holding this option. Such beneficiary or beneficiaries shall
take the transferred option subject to all the terms and conditions of this Agreement, including (without limitation) the limited time
period during which this option may, pursuant to Section 5, be exercised following Optionee’s death.

 

(b)
If this option is designated a Non-Statutory Option in the Grant Notice, then this option may be assigned in whole or in part during
Optionee’s lifetime to one or more members of Optionee’s family or to a trust established for the exclusive benefit of one
or more such family members or to Optionee’s former spouse, to the extent such assignment is in connection with the Optionee’s
estate plan or pursuant to a domestic relations order. The assigned portion shall be exercisable only by the person or persons who acquire
a proprietary interest in the option pursuant to such assignment. The terms applicable to the assigned portion shall be the same as those
in effect for this option immediately prior to such assignment.

 

     

     

    

 

5.
Cessation of Service. The option term specified in Section 1 shall terminate (and this option shall cease to be outstanding) prior
to the Expiration Date should any of the following provisions become applicable:

 

(a)
Should Optionee cease to remain in Service for any reason (other than death, Disability or Cause) while this option is outstanding, then
Optionee (or any person or persons to whom this option is transferred pursuant to a permitted transfer under Section 3) shall have a
period of three (3) months (commencing with the date of such cessation of Service) during which to exercise this option, but in no event
shall this option be exercisable at any time after the Expiration Date.

 

(b)
Should Optionee die while this option is outstanding, then the personal representative of Optionee’s estate or the person or persons
to whom the option is transferred pursuant to Optionee’s will or the laws of inheritance following Optionee’s death or to
whom the option is transferred during Optionee’s lifetime pursuant to a permitted transfer under Section 3 shall have the right
to exercise this option. However, if Optionee dies while holding this option and if Optionee has an effective beneficiary designation
in effect for this option at the time of his or her death, then the designated beneficiary or beneficiaries shall have the exclusive
right to exercise this option following Optionee’s death. Any such right to exercise this option shall lapse, and this option shall
cease to be outstanding, upon the earlier of (i) the expiration of the twelve (12)-month period measured from the date of Optionee’s
death or (ii) the Expiration Date.

 

(c)
Should Optionee cease Service by reason of Disability while this option is outstanding, then Optionee (or any person or persons to whom
this option is transferred pursuant to a permitted transfer under Section 3) shall have a period of twelve (12) months (commencing with
the date of such cessation of Service) during which to exercise this option. In no event shall this option be exercisable at any time
after the Expiration Date.

 

(d)
Should Optionee’s Service be terminated for Cause or should Optionee otherwise engage in Cause while this option is outstanding,
then this option shall terminate immediately and cease to remain outstanding.

 

6.
Adjustment in Option Shares. Should any change be made to the Common Stock by reason of any stock split, stock dividend, recapitalization,
combination of shares, exchange of shares or other change affecting the outstanding Common Stock as a class without the Company’s
receipt of consideration, appropriate adjustments shall be made to (i) the total number and/or class of securities subject to this option
and (ii) the Exercise Price in order to reflect such change and thereby preclude a dilution or enlargement of benefits hereunder.

 

7.
Stockholder Rights. The holder of this option shall not have any stockholder rights with respect to the Option Shares until such
person shall have exercised the option, paid the Exercise Price and become the record holder of the purchased shares.

 

8.
Manner of Exercising Option.

 

(a)
In order to exercise this option with respect to all or any part of the Option Shares for which this option is at the time exercisable,
Optionee (or any other person or persons exercising the option) must take the following actions:

 

(i)
Execute and deliver to the Company a Purchase Agreement for the Option Shares for which the option is exercised.

 

(ii)
Pay the aggregate Exercise Price for the purchased shares in one or more of the following forms:

 

(A)
cash or check made payable to the Company; or

 

     

     

    

 

(B)
a promissory note payable to the Company, but only to the extent authorized by the Company.

 

(iii)
Should the Common Stock be registered under Section 12 of the 1934 Act at the time the option is exercised, then the Exercise Price may
also be paid as follows:

 

(A)
in shares of Common Stock held by Optionee (or any other person or persons exercising the option) for the requisite period necessary
to avoid a charge to the Company’s earnings for financial reporting purposes and valued at Fair Market Value on the Exercise Date;
or

 

(B)
to the extent the option is exercised for Option Shares, through a special sale and remittance procedure pursuant to which Optionee (or
any other person or persons exercising the option) shall concurrently provide irrevocable instructions (a) to a Company-designated brokerage
firm to effect the immediate sale of the purchased shares and remit to the Company, out of the sale proceeds available on the settlement
date, sufficient funds to cover the aggregate Exercise Price payable for the purchased shares plus all applicable income and employment
taxes required to be withheld by the Company by reason of such exercise and (b) to the Company to deliver the certificates for the purchased
shares directly to such brokerage firm in order to complete the sale.

 

Except
to the extent the sale and remittance procedure is utilized in connection with the option exercise, payment of the Exercise Price must
accompany the Purchase Agreement delivered to the Company in connection with the option exercise.

 

(iv)
The exercise price of the Options may also be paid, to the extent permitted by applicable statutes and regulations, either (i) in cash
at the time the Option is exercised, (ii) by delivery to the Company of other Common Stock of the Company valued at its then established
fair market value (as defined below), (iii) by delivery to the Company of either options or stock of the Company including, without
limitation, this Option, valued at the difference between their exercise price and the then established fair market value of the Company’s
Common Stock, (iv) according to a deferred payment or other arrangement (which may include, without limiting the generality of the foregoing,
the use of other Common Stock of the Company) with the holder hereof, or (v) any other form of legal consideration that may be acceptable
to the Board of Directors, in their discretion. For the purposes of this Section 4, the fair market value of the Company’s Common
Stock shall be defined as (i) the closing sale price for the Common Stock on the primary exchange upon which the shares are listed and
traded on the date prior to the date the Option is exercised, or (ii) if the shares are not traded on any national exchange, the closing
sale price for the Common Stock on the NASDAQ National Market on the date prior to the date the Option is exercised, or (iii) if the
shares are neither traded on a national exchange nor listed on the NASDAQ National Market, then the average of the bid and ask prices
for the Common Stock in the Over-The-Counter Market as quoted on the NASDAQ Capital Market, on the date prior to the date the Option
is exercised, or (iv) if the shares of Common Stock are neither traded on a national exchange or the NASDAQ National Market nor quoted
on the NASDAQ Capital Market, the average of the bid and ask prices for the Common Stock as quoted by any recognized securities quotation
service such as the OTC.QB of the OTC Markets Group, LLC or the OTC Electronic Bulletin Board on the date prior to the date the Option
is exercised, or (v) if the shares of Common Stock are not quoted on any recognized securities quotation service such as the OTC.QB of
the OTC Markets Group, LLC or the OTC Electronic Bulletin Board on the date prior to the date the Option is exercised, then the fair
market value of the Company’s Common Stock shall be the price paid for the Company’s Common Stock in the most recent transaction
involving the Company and a nonaffiliated purchaser in an arm’s length transaction (the “Fair Market Value”). In the
case of any deferred payment arrangement, any interest shall be payable at least annually and shall be charged at the minimum rate of
interest necessary to avoid the treatment as interest, under any applicable provisions of the Internal Revenue Code, of any amounts other
than amounts stated to be interest under the deferred payment arrangement.

 

     

     

    

 

(b)
By way of example, in lieu of exercising this Option by payment with cash, certified check or wired funds, the Holder may elect to
receive the number of Shares, as determined below, equal to the value of this Option (or the portion thereof being exercised) by
surrender of this Option at the corporate office of the Company together with the duly executed form of subscription agreement and
notice of such an election, in which event the Company shall issue to the Holder a number of shares of Common Stock computed using
the following formula:

 

	X	=	Y(A-B)
	 	 	A

 

	Where:	X	=	the number of shares of Common Stock to be issued to the Holder
	 	 	 	 
	 	Y	=	the gross number of shares of Common Stock to be purchased
	 	 	 	 
	 	A	=	the Fair Market Value of one (1) share of the Company’s Common Stock
	 	 	 	 
	 	 	 	on
    the day prior to exercise hereunder
	 	 	 	 
	 	B	=	Exercise Price

 

(v)
Furnish to the Company appropriate documentation that the person or persons exercising the option (if other than Optionee) have the right
to exercise this option.

 

(vi)
Execute and deliver to the Company such written representations as may be requested by the Company in order for it to comply with the
applicable requirements of applicable securities laws.

 

(vii)
Make appropriate arrangements with the Company (or Subsidiary or Affiliate employing or retaining Optionee) for the satisfaction of all
applicable income and employment tax withholding requirements applicable to the option exercise.

 

(b)
As soon as practical after the Exercise Date, the Company shall issue to or on behalf of Optionee (or any other person or persons exercising
this option) a certificate for the purchased Option Shares, with the appropriate legends affixed thereto.

 

(c)
In no event may this option be exercised for any fractional shares.

 

9.
Compliance with Laws and Regulations.

 

(a)
The exercise of this option and the issuance of the Option Shares upon such exercise shall be subject to compliance by the Company and
Optionee with all applicable requirements of law relating thereto and with all applicable regulations of any stock exchange (or the Nasdaq
National Market, if applicable) on which the Common Stock may be listed for trading at the time of such exercise and issuance.

 

(b)
The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the
lawful issuance and sale of any Common Stock pursuant to this option shall relieve the Company of any liability with respect to the non-issuance
or sale of the Common Stock as to which such approval shall not have been obtained. The Company, however, shall use its best efforts
to obtain all such approvals.

 

10.
Successors and Assigns. Except to the extent otherwise provided in Sections 3 and 6, the provisions of this Agreement shall inure
to the benefit of, and be binding upon, the Company and its successors and assigns and Optionee, Optionee’s assigns and the legal
representatives, heirs and legatees of Optionee’s estate.

 

     

     

    

 

11.
Notices. Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and
addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to Optionee shall be in writing
and addressed to Optionee at the address indicated below Optionee’s signature line on the Grant Notice. All notices shall be deemed
effective upon personal delivery or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified.

 

12.
Governing Law. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of
Colorado without resort to that State’s conflict-of-laws rules.

 

	VITRO
    DIAGNOSTICS, INC.	 	OPTIONEE
	 	 	 	 	 
	By:	/s/
    James Musick	 	 	/s/
    James Musick
	 	James
    Musick, CEO	 	 	James
    Musick

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]